Light AI completes V1.0 diagnostic software system

Executive Summary

• Light AI Inc. has completed Version 1.0 of its commercial software platform, which uses proprietary AI algorithms to analyze smartphone images for diagnostic purposes.
• The initial focus is on detecting Group A Streptococcus (GAS) in pharyngitis cases, offering rapid results without the need for swabs or lab tests.
• The company plans to initiate a pilot study with a major global healthcare provider to validate performance in a real-world clinical setting, paving the way for commercial distribution.

Key Details

• Software Completion: Version 1.0 of the commercial software platform is complete.
• Technology: Proprietary AI algorithms analyze smartphone images (iOS and Android) to detect Group A Streptococcus.
• Validation Metrics: Pre-FDA validation studies showed a 96.57% accuracy rate in differentiating viral and bacterial pharyngitis, with a 100% negative predictive value for Streptococcus A infection.
• Pilot Study: A pilot study with a major global healthcare provider is planned to confirm performance in managing pharyngitis in urgent care settings.
• Future Expansion: The platform is designed to expand into other diagnostic areas, including eye and skin conditions, and potentially COVID-19.
• Market Context: Viral and GAS pharyngitis affects over 600 million people annually worldwide; untreated GAS can lead to rheumatic heart disease, imposing a global economic burden exceeding $1 trillion annually.

Notable Quotes

• "This milestone marks our transition from development to commercialization. Our technology is built to provide real-time diagnostic insights, helping reduce unnecessary physician visits, lower testing costs and curb antibiotic overuse." — Peter Whitehead, CEO